U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502495) titled 'Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets' on March 26.
Brief Summary: This is a Phase 2, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic medications.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervention:
DRUG: icovamenib 100mg
icovamenib 100mg
DRUG: Placebo
Matching placebo
Recruitment Status: RECRUITING
Sponsor: Biomea Fusion Inc.
Published by HT Digital Content Se...